Cullinan Oncology, Inc. — Form 10-K Summary
Business context and reporting period
The filing covers the fiscal year ended December 31, 2020. The audited financial statements are presented for Cullinan Oncology, LLC and subsidiaries, the predecessor structure to Cullinan Oncology, Inc. The company completed a reorganization immediately before its January 2021 IPO and changed its name to Cullinan Oncology, Inc. in February 2021. Common stock began trading on Nasdaq under CGEM on January 8, 2021.
Cullinan is an early-stage biopharmaceutical company developing a diversified pipeline of targeted oncology and immuno-oncology therapies through a central “hub-and-spoke” structure. Its lead clinical program was CLN-081, while CLN-049, CLN-619 and CLN-617 were in preclinical or IND-enabling development. The company had no approved products and no product-sale revenue.
Financial results and key metrics
| Metric | 2019 | 2020 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No product revenue |
| Research and development expense | $16.8 million | $43.2 million | +$26.4 million |
| General and administrative expense | $5.5 million | $17.1 million | +$11.6 million |
| Total operating expenses | $22.3 million | $60.3 million | +$38.1 million |
| Loss from operations | $(22.3) million | $(60.3) million | Greater operating loss |
| Other income, net | $0.6 million | $0.9 million | +$0.3 million |
| Net loss | $(21.7) million | $(59.5) million | Loss increased |
| Net loss attributable to Cullinan | $(20.7) million | $(51.8) million | Loss increased |
| Net loss per unit | $(3.23) | $(5.48) | More negative |
| Net cash used in operating activities | $(20.9) million | $(29.8) million | Higher cash burn |
| Cash, cash equivalents and short-term investments at year-end | $98.6 million | $210.2 million | +$111.6 million |
Research and development spending increased primarily because of the acquisition and development of CLN-619, higher preclinical and chemistry, manufacturing and controls costs for CLN-049, increased CLN-081 enrollment, expanded early-stage research, and $5.9 million of equity-based compensation. General and administrative expense increased because of headcount, public-company preparation, professional services and $9.0 million of equity-based compensation.
At December 31, 2020, the company reported total assets of $214.7 million, current liabilities of $14.3 million, total liabilities of $14.4 million and an accumulated deficit of $93.3 million. The filing does not identify material funded debt; the principal contractual obligation disclosed was $2.1 million of operating lease commitments through 2024.
Financing activities provided $140.1 million in 2020, including $14.0 million of Series B preferred-unit proceeds and $124.8 million of Series C proceeds. Investing activities used $5.4 million. The company had negative operating cash flow and expects continued losses.
Material changes versus the prior comparable period
- Net loss increased from $21.7 million to $59.5 million, while operating expenses rose from $22.3 million to $60.3 million.
- Research and development expense increased by approximately 157%, reflecting a broader and more advanced pipeline.
- Cash and short-term investments more than doubled because of preferred-unit financings, despite increased operating cash burn.
- Cullinan acquired control of Cullinan MICA in May 2020 and recorded $6.4 million of acquired in-process research and development expense related to CLN-619.
- The company discontinued the VK-2019/Apollo program in May 2020 after determining that development should cease.
- In December 2020, Cullinan licensed CLN-081 rights in Greater China to Zai Lab for a $20.0 million upfront payment, potential milestones of up to $211.0 million and tiered royalties. The upfront payment was received and recognized in the first quarter of 2021, not 2020.
- CLN-081 clinical enrollment progressed, with 37 patients dosed and 25 evaluable as of November 10, 2020. Among evaluable patients, 10 had partial responses, 14 had stable disease and one had progressive disease.
Guidance, outlook, risks and unusual items
Management stated that the $210.2 million of year-end 2020 cash, cash equivalents and short-term investments, together with $264.7 million of net IPO proceeds received in January 2021, was expected to fund operations through 2024 under its current plan. This is not a commitment and depends on development costs, enrollment, regulatory outcomes, manufacturing requirements and other assumptions. The company expects substantial additional research and development and public-company expenses and does not expect near-term product revenue.
- CLN-081 entered a Phase 2a dose expansion at 100 mg twice daily in February 2021, with a planned enrollment of up to 36 patients and a clinical update anticipated in mid-2021.
- The company expected to submit a CLN-619 IND in the second quarter of 2021 and an IND for CLN-617 in 2022.
- Although the company submitted a CLN-049 IND in January 2021, it withdrew the application after FDA feedback requesting consideration of alternative trial designs and additional pharmacokinetic and pharmacodynamic information.
- CLN-081 data were preliminary, based on a small, open-label study with limited follow-up. The filing warns that response and safety results may change as additional patients are enrolled and data are verified.
- Reported CLN-081 safety findings included one dose-limiting Grade 3 treatment-related diarrhea event, one other Grade 3 treatment-related anemia event, treatment-related rash and diarrhea. The company cautioned that more severe adverse events could emerge.
- COVID-19 affected the pace of clinical-trial enrollment and preclinical studies, although management reported no material financial impact or significant operational disruption through the filing date.
- The company relies heavily on third-party CROs, CMOs and other vendors, including single-source manufacturers for certain biologic drug substances. Manufacturing interruptions, clinical delays, patient-enrollment challenges, regulatory holds, adverse safety findings and intellectual-property disputes could materially affect results.
- The hub-and-spoke model creates ownership and control risks. Cullinan owned approximately 80% of Cullinan Pearl, 90% of Cullinan Amber, 92% of Cullinan Florentine and 35% of Cullinan MICA on a fully diluted basis as of February 28, 2021. Additional subsidiary financing could dilute Cullinan’s interests.
- The company had no material litigation identified by management as likely to have a material adverse effect. It also reported no off-balance-sheet arrangements.
Most important facts for an investor to verify
- Whether CLN-081’s preliminary response rate, durability, central nervous system activity and tolerability are confirmed in larger and longer-followed datasets.
- The revised clinical and regulatory path for CLN-049 after withdrawal of its IND and the timing of the CLN-619 IND and first clinical dosing.
- Actual quarterly cash burn and whether the stated funding runway through 2024 remains valid as programs advance.
- The timing and accounting treatment of the $20.0 million Zai Lab upfront payment, as well as the probability and economics of future milestones and royalties.
- Ownership, governance, financing and dilution terms for Cullinan MICA and the other partially owned subsidiaries.
- Third-party manufacturing capacity, supply redundancy and compliance for CLN-049, CLN-619 and future clinical programs.
- Patent scope, remaining term, license obligations, royalties, milestone commitments and change-of-control or sale-related payments.
- The impact of equity compensation, the January 2021 IPO, the reverse stock split and future equity-plan share increases on per-share ownership and valuation.